Insider Trading February 20, 2026

Align Technology CFO Disposes $1.5M in Stock as Company Posts Strong Q4 Results

John Morici sold 7,969 shares on Feb. 18, 2026; Align reports earnings and revenue above expectations and draws analyst upgrades

By Marcus Reed ALGN
Align Technology CFO Disposes $1.5M in Stock as Company Posts Strong Q4 Results
ALGN

Align Technology EVP and CFO John Morici sold 7,969 shares on February 18, 2026, generating roughly $1.5 million. The transaction, disclosed in a Form 4 filing with the Securities and Exchange Commission, took place at prices between $189.05 and $189.65. The company also reported fourth-quarter 2025 results that beat estimates, prompting several analyst price-target increases.

Key Points

  • CFO John Morici sold 7,969 shares on February 18, 2026, for about $1.5 million at prices between $189.05 and $189.65; he now directly owns 8,237 shares.
  • Align beat fourth-quarter 2025 estimates with EPS of $3.29 (vs. $2.97 expected) and revenue of $1.05 billion (vs. $1.03 billion expected), with 5% year-over-year growth driven by aligners and scanners.
  • Analysts increased price targets after the quarter: HSBC to $200 (upgrade to Buy), Piper Sandler to $220 (Overweight retained), and Stifel to $210, while gross margin reached 72.0%.

Summary

Align Technology's (NASDAQ:ALGN) executive vice president and chief financial officer, John Morici, sold 7,969 shares of common stock on February 18, 2026, for approximately $1.5 million. The shares were sold at per-share prices ranging from $189.05 to $189.65. The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Following the disposition, Morici directly holds 8,237 shares of Align Technology. That total includes 183 shares acquired on January 30, 2026, under the ALGN Employee Stock Purchase Plan. At the time of reporting, Align's shares traded at $190.09, representing a 35% increase over the prior six months.

Valuation snapshot

According to InvestingPro analysis, the stock appears undervalued at current levels, with Align maintaining a market capitalization of $13.63 billion. For investors seeking additional company-level research, a comprehensive Pro Research Report covering Align and more than 1,400 other U.S. equities is available.

Quarterly performance

Align reported fourth-quarter 2025 earnings that exceeded analyst expectations. The company posted earnings per share of $3.29, versus the forecast of $2.97. Revenue for the quarter reached $1.05 billion, topping the expected $1.03 billion and marking 5% year-over-year growth. Management attributed the expansion to balanced increases across teen and adult aligners as well as scanner products.

Adult aligner shipments rose 8% year-over-year, reaching their highest level since 2021. The company also reported double-digit growth in doctor-supported organizations during the quarter. In addition, Align recorded a gross margin of 72.0%, noted as the company’s best margin result since the first quarter of 2022.

Analyst reactions

Following the quarterly release, multiple financial firms adjusted their outlooks. HSBC upgraded Align from Hold to Buy and set a price target of $200, citing the potential of 3D printing. Piper Sandler raised its price target to $220 while maintaining an Overweight rating, and Stifel increased its target to $210, highlighting strong case volume growth of 7.7% in the fourth quarter.

Regulatory filing

The insider sale was recorded via a Form 4 filing with the Securities and Exchange Commission, documenting the transaction and updated beneficial ownership details for Morici.

Context and next steps

The combination of insider selling, a valuation assessment from InvestingPro, and upgraded analyst targets provides investors with multiple data points to weigh. Those seeking more detailed financial and valuation analysis can consult the available Pro Research Report for Align and other U.S. equities.

Risks

  • Insider sale was disclosed in a Form 4 filing; while the transaction is documented, insider selling can create investor perception uncertainty in the capital markets and healthcare technology sectors.
  • Valuation assessments show divergence - InvestingPro labels the stock undervalued at a $13.63 billion market cap while analyst price targets range from $200 to $220, indicating differing views on fair value that affect equity investors.
  • Company growth relies on continued demand for teen and adult aligners plus scanner products; shipment and case-volume trends will influence revenue and margin performance in the medical devices and dental technology sectors.

More from Insider Trading

CSX Executive Sells $3.74M in Shares, Exercises Options Amid Earnings Miss and Leadership Change Feb 20, 2026 HCSG Executive Sells Nearly $916,000 in Stock as Earnings Beat Drives Analyst Upgrades Feb 20, 2026 Morningstar Executive Chairman Sells 13,858 Shares in $2.2M Transaction Feb 20, 2026 Ensign Group Legal Chief Disposes $105,115 in Stock After Option Exercise Feb 20, 2026 Ryder Executive Sells $597K in Shares as Stock Trades Near Yearly Peak Feb 20, 2026